AbbVie, schizophrenia

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie shares are down 12.4%. In a statement,
Advantage BMS as AbbVie drug fails schizophrenia trials
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended a 10-year hiatus in new-mechanism therapies for the disorder when it got FDA approval for Cobenfy (xanomeline tartrate/trospium chloride) in September. Shares in BMS rose nearly 12% after AbbVie's announcement.
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for next steps.
Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure
Leerink analyst David Risinger upgraded Bristol Myers (BMY) to Outperform from Market Perform with a price target of $73, up from $55. The firm
Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail Sentiment
Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after AbbVie's ($ABBV) experimental schizophrenia treatment failed in a pair of mid-stage studies.
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
pharmaphorum4d
BMS ends decades-long drought in novel schizophrenia drugs
Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has ...
Seeking Alpha14d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy ... In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Business Insider4d
Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia missed ... while those of competitor Bristol ...
Reuters16d
Bristol-Myers Squibb Co
Bristol Myers wins US FDA approval for new type of schizophrenia drug Healthcare & Pharmaceuticalscategory· September 27, 2024 2seventy bio will discontinue enrolling patients in a late-stage ...
The Associated Press on MSN15d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
In contrast to the weight gain seen with other schizophrenia drugs, people lost a few pounds while taking Cobenfy, made by ...
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...